查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529818

尿失禁治疗药物市场规模、份额、趋势分析报告：按类型、药物类别、性别、分销管道、地区、细分市场预测，2024-2030年

Urinary Incontinence Therapeutics Market Size, Share & Trends Analysis Report By Type (Stress, Urge, Overflow, Functional Incontinence), By Drug Class, By Gender, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

市场规模及趋势

由于人口老化中尿失禁（UI）盛行率的增加以及对可用治疗方案的认识不断增强，预计到2023 年，尿失禁药物的全球市场规模将达到43.7 亿美元，预计将以复合年增长率扩大。根据Dovepress 2023年5月的报告，女性尿失禁的盛行率为24.8%，其中压力性尿失禁最常见，为12.7%，其次是混合性尿失禁，为8.0%，急性尿失禁为4.1%。这项研究强调，UI 的盛行率随着年龄和体重指数 (BMI) 的增加而逐渐增加。

该市场包括多种药物，包括抗胆碱能药物、β3-肾上腺素促效剂和局部雌激素。这些药物透过减少膀胱收缩、增加膀胱容量以及强化尿道和阴道组织来帮助控制症状。市场参与者不断投资于研发，以推出更有效、更安全的治疗方法，这推动了市场的成长。

人口老化是该市场成长的主要动力。随着全球预期寿命的延长，老年人口数量不断增加，导致包括 UI 在内的与老龄化相关的疾病的盛行率增加。由于骨盆底肌肉衰弱、膀胱容量减少以及其他影响泌尿功能的健康状况，老年人经常会出现膀胱控制问题。这种人口结构的变化极大地促进了对治疗药物解决方案不断增长的需求，以管理和缓解这些疾病。

在全球范围内，60 岁及以上的人口预计将从 2020 年的 10 亿增加一倍，达到 2050 年的 21 亿。随着人口老化，UI 和其他老年综合症（如跌倒和谵妄）的负担预计会增加。这种成长需要更有效和更容易获得的治疗方法，从而推动了这一领域的研究和发展。因此，医疗保健提供者致力于透过更好地管理 UI 来提高老年人的生活品质。因此，市场正在扩大，公司正在投资创新疗法，以满足不断增长的患者群体的需求。

此外，药物开发的进步也为该市场的成长做出了重大贡献。研究人员和製药公司致力于开发疗效更好、副作用更少、给药方法更改良的新药。缓释性和联合治疗等创新正在改善患者的依从性和药物结果。例如，2024 年 4 月，Lupin Ltd 在美国推出了Mirabegron），这是 Mybetriq 的非专利替代品，用于治疗膀胱过动症。此外，对新药物标靶和作用机制的探索正在导致更有效的治疗药物的引入。这些进步不仅改善了患者的生活质量，还透过提供优质的治疗选择推动了市场扩张。

此外，近年来，人们对尿失禁的认识和诊断显着增加。医疗机构和製药公司所进行的健康宣传活动和教育计画在减少与这种疾病相关的耻辱和鼓励人们寻求医疗建议方面发挥着重要作用。此外，诊断工具和方法的改进使医疗保健专业人员更容易识别和分类不同类型的尿失禁，从而製定更个人化和有效的治疗计划。由于认识的提高和诊断能力的提高，尿失禁治疗药物的患者基础正在扩大。

全球尿失禁药物市场细分报告

该报告预测了2018年至2030年国家层级的收益成长，并对每个子区隔的最新行业趋势和商机进行了分析。研究报告按类型、性别、分销管道、药物类别和地区对全球尿失禁治疗药物市场进行分类。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章：尿失禁药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 尿失禁治疗药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 管道分析

第四章 尿失禁治疗药物市场：按类型估计和趋势分析

  • 尿失禁治疗药物细分市场细分仪表板
  • 尿失禁治疗药物市场：按类型的变化分析
  • 不同类型尿失禁治疗药物市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 应力性尿失禁
  • 急性尿失禁
  • 溢流性尿失禁
  • 功能性失禁
  • 其他的

第五章 尿失禁治疗药物市场：依药物类别估计与趋势分析

  • 尿失禁治疗药物细分市场细分仪表板
  • 尿失禁治疗药物市场：依药物类别波动分析
  • 按药物类别分類的尿失禁治疗药物市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 抗胆碱能药物
  • Beta3肾上腺素受体促效剂
  • α阻断剂
  • 雌激素
  • 去氨加压素
  • 三环抗忧郁药物
  • 其他的

第六章 尿失禁治疗药物市场：依通路估算与趋势分析

  • 尿失禁治疗药物细分市场细分仪表板
  • 尿失禁治疗药物市场：按分销管道波动分析
  • 按分销管道分類的尿失禁治疗药物市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 医院药房
  • 零售药房
  • 网路药房

第七章 尿失禁治疗药物市场：性别、估计与趋势分析

  • 尿失禁治疗药物细分市场细分仪表板
  • 尿失禁治疗药物市场：性别差异分析
  • 性别尿失禁治疗药物市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 男性
  • 女士

第八章 尿失禁治疗药物市场：区域估计与趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 市场参与企业分类
  • 主要企业简介
    • Pfizer Inc.
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Johnson &Johnson
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • GlaxoSmithKline plc
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Bayer AG
    • Ferring Pharmaceuticals
Product Code: GVR-4-68040-366-2

Market Size & Trends

The global urinary incontinence therapeutics market size was estimated at USD 4.37 billion in 2023 and is projected to expand at a CAGR of 4.0% from 2024 to 2030 due to the increasing prevalence of urinary incontinence (UI) among aging populations and the rising awareness about available treatments. According to a May 2023 report by Dovepress, the prevalence of female UI was found to be 24.8%, with stress UI being the most common subtype at 12.7%, followed by mixed UI at 8.0%, and urgency UI at 4.1%. The study highlighted that the prevalence of UI increased progressively with age and body mass index (BMI).

This market includes a variety of medications such as anticholinergics, beta-3 adrenergic agonists, and topical estrogens. These drugs help manage symptoms by reducing bladder contractions, increasing bladder capacity, and strengthening urethral and vaginal tissues. Market players are continuously investing in research and development to introduce more effective and safer treatments, which is propelling market growth.

The aging population is majorly driving the growth of this market. As global life expectancy increases, the number of elderly individuals is rising, leading to a higher prevalence of age-related conditions, including UI. Older adults often experience bladder control issues due to weakened pelvic floor muscles, decreased bladder capacity, and other health conditions that impact urinary function. This demographic shift significantly contributes to the growing demand for therapeutic solutions to manage and alleviate these symptoms.

Globally, the number of people aged 60 and older is projected to double from 1 billion in 2020 to 2.1 billion by 2050. As the population ages, the burden of UI and other geriatric syndromes like falls and delirium is expected to grow. This increase necessitates more effective and accessible treatments, driving research and development in this sector. Consequently, healthcare providers are focusing on improving the quality of life for older adults through better management of UI. As a result, the market is expanding, with companies investing in innovative treatments to meet the needs of this growing patient population.

In addition, advancements in drug development are significantly contributing to the growth of this market. Researchers and pharmaceutical companies are focusing on developing new drugs with better efficacy, fewer side effects, and improved delivery methods. Innovations such as extended-release formulations and combination therapies are enhancing patient compliance and treatment outcomes. For instance, in April 2024, Lupin Ltd introduced Mirabegron, a generic alternative to Mybetriq, aimed at managing overactive bladder in the U.S. Additionally, the exploration of novel drug targets and mechanisms of action is leading to the introduction of more effective therapies. These advancements not only improve the quality of life for patients but also drive market expansion by offering superior treatment options.

Furthermore, there has been a notable increase in awareness and diagnosis of urinary incontinence in recent years. Health campaigns and educational programs by healthcare organizations and pharmaceutical companies have played a crucial role in reducing the stigma associated with this condition and encouraging individuals to seek medical advice. Improved diagnostic tools and methods have also made it easier for healthcare providers to identify and classify different types of urinary incontinence, leading to more personalized and effective treatment plans. This heightened awareness and better diagnostic capabilities are expanding the patient base for UI therapeutics.

Global Urinary Incontinence Therapeutics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global urinary incontinence therapeutics market report based on type, gender, distribution channel, drug class, and region.

  • Type Outlook (Revenue, USD Billion; 2018 - 2030)
  • Stress Incontinence
  • Urge Incontinence
  • Overflow Incontinence
  • Functional Incontinence
  • Other Types
  • Drug Class Outlook (Revenue, USD Billion; 2018 - 2030)
  • Anticholinergics
  • Beta-3 Adrenoceptor Agonists
  • Alpha Blockers
  • Estrogen
  • Desmopressin
  • Tricyclic Antidepressants
  • Other Drug Classes
  • Gender Outlook (Revenue, USD Billion; 2018 - 2030)
  • Male
  • Female
  • Distribution Channel Outlook (Revenue, USD Billion; 2018 - 2030)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Billion; 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Norway

Denmark

Sweden

  • Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

  • Latin America

Brazil

Argentina

  • Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Age
    • 1.2.3. Distribution Channel
    • 1.2.4. Drug Class
    • 1.2.5. Regional Scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Age outlook
    • 2.2.3. Distribution channel outlook
    • 2.2.4. Drug class outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Urinary Incontinence Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Urinary Incontinence Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Urinary Incontinence Therapeutics Market: Type Estimates & Trend Analysis

  • 4.1. Urinary Incontinence Therapeutics Market Segment Dashboard
  • 4.2. Urinary Incontinence Therapeutics Market: Type Movement Analysis
  • 4.3. Urinary Incontinence Therapeutics Market by Type Outlook (USD Billion)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Stress Incontinence
    • 4.5.1. Stress Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.6. Urge Incontinence
    • 4.6.1. Urge Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.7. Overflow Incontinence
    • 4.7.1. Overflow Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.8. Functional Incontinence
    • 4.8.1. Functional Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.9. Others
    • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Urinary Incontinence Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 5.1. Urinary Incontinence Therapeutics Market Segment Dashboard
  • 5.2. Urinary Incontinence Therapeutics Market: Drug Class Movement Analysis
  • 5.3. Urinary Incontinence Therapeutics Market by Drug Class Outlook (USD Billion)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Anticholinergics
    • 5.5.1. Anticholinergics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Beta-3 Adrenoceptor Agonists
    • 5.6.1. Beta-3 Adrenoceptor Agonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.7. Alpha Blockers
    • 5.7.1. Alpha Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.8. Estrogen
    • 5.8.1. Estrogen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.9. Desmopressin
    • 5.9.1. Desmopressin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.10. Tricyclic Antidepressants
    • 5.10.1. Tricyclic Antidepressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.11. Others
    • 5.11.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Urinary Incontinence Therapeutics Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Urinary Incontinence Therapeutics Market Segment Dashboard
  • 6.2. Urinary Incontinence Therapeutics Market: Distribution Channel Movement Analysis
  • 6.3. Urinary Incontinence Therapeutics Market by Distribution Channel Outlook (USD Billion)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospital Pharmacies
    • 6.5.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.6. Retail Pharmacies
    • 6.6.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.7. Online Pharmacies
    • 6.7.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Urinary Incontinence Therapeutics Market: Gender Estimates & Trend Analysis

  • 7.1. Urinary Incontinence Therapeutics Market Segment Dashboard
  • 7.2. Urinary Incontinence Therapeutics Market: Gender Movement Analysis
  • 7.3. Urinary Incontinence Therapeutics Market by Gender Outlook (USD Billion)
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Male
    • 7.5.1. Male Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Female
    • 7.6.1. Female Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Urinary Incontinence Therapeutics Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Key Company Profiles
    • 9.2.1. Pfizer Inc.
      • 9.2.1.1. Company overview
      • 9.2.1.2. Financial performance
      • 9.2.1.3. Age benchmarking
      • 9.2.1.4. Strategic initiatives
    • 9.2.2. AbbVie Inc.
      • 9.2.2.1. Company overview
      • 9.2.2.2. Financial performance
      • 9.2.2.3. Age benchmarking
      • 9.2.2.4. Strategic initiatives
    • 9.2.3. Astellas Pharma Inc.
      • 9.2.3.1. Company overview
      • 9.2.3.2. Financial performance
      • 9.2.3.3. Age benchmarking
      • 9.2.3.4. Strategic initiatives
    • 9.2.4. Johnson & Johnson
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Age benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. Viatris Inc.
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Age benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. Teva Pharmaceutical Industries Ltd.
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Age benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. Sanofi S.A.
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Age benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. GlaxoSmithKline plc
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Age benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Boehringer Ingelheim Pharmaceuticals, Inc.
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Age benchmarking
      • 9.2.9.4. Strategic initiatives
      • 9.2.9.5. Strategic initiatives
      • 9.2.9.6. Strategic initiatives
    • 9.2.10. Bayer AG
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Age benchmarking
      • 9.2.10.4. Strategic initiatives
      • 9.2.10.5. Strategic initiatives
    • 9.2.11. Ferring Pharmaceuticals
      • 9.2.11.1. Company overview
      • 9.2.11.2. Financial performance
      • 9.2.11.3. Age benchmarking
      • 9.2.11.4. Strategic initiatives
      • 9.2.11.5. Strategic initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 4. Global urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 5. Global urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 6. Global urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 7. North America urinary incontinence therapeutics market, by region, 2018 - 2030, (USD Billion)
  • Table 8. North America urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 9. North America urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 10. North America urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 11. North America urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 12. U.S. urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 13. U.S. urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 14. U.S. urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 15. U.S. urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 16. Canada urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 17. Canada urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 18. Canada urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 19. Canada urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 20. Mexico urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 21. Mexico urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 22. Mexico urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 23. Mexico urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 24. Europe urinary incontinence therapeutics market, by country, 2018 - 2030, (USD Billion)
  • Table 25. Europe urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 26. Europe urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 27. Europe urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 28. Europe urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 29. UK urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 30. UK urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 31. UK urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 32. UK urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 33. Germany urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 34. Germany urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 35. Germany urinary incontinence therapeutics market, by distribution channel 2018 - 2030, (USD Billion)
  • Table 36. Germany urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 37. France urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 38. France urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 39. France urinary incontinence therapeutics market, by distribution channel 2018 - 2030, (USD Billion)
  • Table 40. France urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 41. Italy urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 42. Italy urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 43. Italy urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 44. Italy urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 45. Spain urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 46. Spain urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 47. Spain urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 48. Spain urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 49. Denmark urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 50. Denmark urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 51. Denmark urinary incontinence therapeutics market, by distribution channel 2018 - 2030, (USD Billion)
  • Table 52. Denmark urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 53. Norway urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 54. Norway urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 55. Norway urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 56. Norway urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 57. Sweden urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 58. Sweden urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 59. Sweden urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 60. Sweden urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 61. Asia Pacific urinary incontinence therapeutics market, by country, 2018 - 2030, (USD Billion)
  • Table 62. Asia Pacific urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 63. Asia Pacific urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 64. Asia Pacific urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 65. Asia Pacific urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 66. Japan urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 67. Japan urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 68. Japan urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 69. Japan urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 70. China urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 71. China urinary incontinence therapeutics market, by gender 2018 - 2030, (USD Billion)
  • Table 72. China urinary incontinence therapeutics market, by distribution channel 2018 - 2030, (USD Billion)
  • Table 73. China urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 74. India urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 75. India urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 76. India urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 77. India urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 78. Australia urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 79. Australia urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 80. Australia urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 81. Australia urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 82. South Korea urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 83. South Korea urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 84. South Korea urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 85. South Korea urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 86. Thailand urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 87. Thailand urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 88. Thailand urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 89. Thailand urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 90. Latin America urinary incontinence therapeutics market, by country, 2018 - 2030, (USD Billion)
  • Table 91. Latin America urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 92. Latin America urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 93. Latin America urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 94. Latin America urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 95. Brazil urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 96. Brazil urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 97. Brazil urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 98. Brazil urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 99. Argentina urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 100. Argentina urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 101. Argentina urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 102. Argentina urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 103. Middle East & Africa urinary incontinence therapeutics market, by country, 2018 - 2030, (USD Billion)
  • Table 104. Middle East & Africa urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 105. Middle East & Africa urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 106. Middle East & Africa urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 107. Middle East & Africa urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 108. South Africa urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 109. South Africa urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 110. South Africa urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 111. South Africa urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 112. Saudi Arabia urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 113. Saudi Arabia urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 114. Saudi Arabia urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 115. Saudi Arabia urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 116. UAE urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 117. UAE urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 118. UAE urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 119. UAE urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)
  • Table 120. Kuwait urinary incontinence therapeutics market, by type, 2018 - 2030, (USD Billion)
  • Table 121. Kuwait urinary incontinence therapeutics market, by gender, 2018 - 2030, (USD Billion)
  • Table 122. Kuwait urinary incontinence therapeutics market, by distribution channel, 2018 - 2030, (USD Billion)
  • Table 123. Kuwait urinary incontinence therapeutics market, by drug class, 2018 - 2030, (USD Billion)

List of Figures

  • Fig. 1. Information procurement
  • Fig. 2. Primary research pattern
  • Fig. 3. Market research approaches
  • Fig. 4. Value chain-based sizing & forecasting
  • Fig. 5. Market formulation & validation
  • Fig. 6. Urinary incontinence therapeutics market segmentation
  • Fig. 7. Market driver analysis (current & future impact)
  • Fig. 8. Market restraint analysis (current & future impact)
  • Fig. 9. SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10. Porter's five forces analysis
  • Fig. 11. Urinary incontinence therapeutics market, type outlook key takeaways (USD billion)
  • Fig. 12. Urinary incontinence therapeutics market: type movement analysis (USD billion), 2023 & 2030
  • Fig. 13. Stress incontinence market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 14. Urge incontinence market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 15. Overflow Incontinence market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 16. Functional Incontinence market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 17. Others market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 18. Urinary incontinence therapeutics market, gender outlook key takeaways (USD billion)
  • Fig. 19. Urinary incontinence therapeutics market: gender movement analysis (USD billion), 2023 & 2030
  • Fig. 20. Male market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 21. Female market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 22. Urinary incontinence therapeutics market, distribution channel outlook key takeaways (USD billion)
  • Fig. 23. Urinary incontinence therapeutics market: distribution channel movement analysis (USD billion), 2023 & 2030
  • Fig. 24. Hospital pharmacies market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 25. Retail pharmacies market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 26. Online pharmacies market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 27. Urinary incontinence therapeutics market, drug class outlook key takeaways (USD billion)
  • Fig. 28. Urinary incontinence therapeutics market: drug class movement analysis (USD billion), 2023 & 2030
  • Fig. 29. Anticholinergics market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 30. Beta-3 adrenoceptor agonists market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 31. Alpha blockers market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 32. Estrogen market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 33. Desmopressin market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 34. Tricyclic antidepressants market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 35. Others market revenue estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 36. Urinary incontinence therapeutics market: regional key takeaways (USD billion)
  • Fig. 37. Urinary incontinence therapeutics market: regional outlook, 2023 & 2030, USD billion
  • Fig. 38. North America urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 39. U.S. urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 40. Canada urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 41. Mexico urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 42. Europe urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 43. UK urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 44. Germany urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 45. France urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 46. Spain urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 47. Italy urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 48. Norway urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 49. Denmark urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 50. Sweden urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 51. Asia Pacific urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 52. China urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 53. Japan urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 54. India urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 55. South Korea urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 56. Australia urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 57. Thailand urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 58. Latin America urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 59. Brazil urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 60. Argentina urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 61. Middle East and Africa urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 62. South Africa urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 63. Saudi Arabia urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 64. UAE urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 65. Kuwait urinary incontinence therapeutics market estimates and forecasts, 2018 - 2030 (USD billion)
  • Fig. 66. List of key emerging company's/distribution channel disruptors/innovators